Latest Revenue Growth News

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.

Telix Pharmaceuticals posted an 11% increase in Q1 2026 revenue to US$230 million, reaffirmed full-year guidance, and reported progress in multiple clinical trials including its lead prostate cancer therapy TLX591-Tx.

Pure Foods Tasmania has agreed to acquire premium seafood brand Brilliant Food Australia, adding $1.3 million in annual revenue and expanding its national footprint.

Frontier Digital Ventures reported a sharp 18% revenue decline in FY2025 due to shedding low-margin businesses, yet achieved a remarkable 205% jump in EBITDA, signalling a successful pivot to core classifieds in emerging markets.

Acrow Limited has reported record new hire contracts and a robust sales pipeline, confirming FY26 guidance and issuing optimistic initial guidance for FY27 revenue and earnings.

Adveritas Limited has launched an upgraded self-serve TrafficGuard™ platform targeting over 200 million small to medium enterprises globally, marking a significant expansion in its total addressable market and revenue potential.

Enlitic has secured a $250,000 data migration contract with St. Jude Children’s Research Hospital, marking its first foray into paediatric healthcare and opening doors for its AI-powered platform Ensight.

Xenitra Limited has secured a $30 million AUD sales agreement for Danone products with Rockcheck Group and established its Australian subsidiary as an authorised supplier, marking a major step in its China market strategy.

Atomo Diagnostics stands to gain significantly as Lumos Diagnostics’ FebriDx test secures FDA CLIA waiver approval, vastly expanding its US market potential. This regulatory milestone triggers substantial contracted revenues and prompts Atomo to ramp up production.

RocketBoots has secured a significant A$3.3 million activation contract with a leading multinational retailer, marking the start of a global deployment phase that complements its existing SaaS agreement and promises near-term revenue growth.

Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, paving the way for entry into Southeast Asia’s largest market. This milestone marks a significant step in the company’s international expansion strategy.

Catapult Sports projects record Annualized Contract Value growth of up to 28% and a 50% jump in Management EBITDA for FY26, underpinned by strategic acquisitions and strong subscription revenue.